Germline predisposition to soft tissue sarcoma

Abstract

Soft tissue sarcoma (STS) most often occurs sporadically, but can also arise in the setting of a germline cancer predisposition syndrome (CPS). There is significant diversity amongst STS diagnoses as these tumors exhibit a variety of histologies, occur in all age groups, and can occur in any location in the body. This diversity is also reflected in the many known associated germline cancer predisposition associations. Some STS diagnoses, such as anaplastic rhabdomyosarcoma, are associated with high heritability and other STS, such as Ewing sarcoma, are notably absent from known CPS. Recognizing when a STS is more likely to be hereditary can influence clinical management. Individuals diagnosed with STS due to CPS may be at risk for other malignancies and should undergo additional surveillance for early detection. Additionally, family members should undergo genetic testing as they also may be at risk to develop STS and other CPS-associated malignancies. Some underlying cancer predisposition diagnoses may have implications for the treatment of a concurrent malignancy as in the case of PARP inhibitor therapy in the setting of homologous recombination deficiency. This review summarizes current knowledge of selected STS and their associations with CPS.

Keywords

Genetic / soft tissue sarcoma / Li-Fraumeni syndrome / cancer predisposition syndrome

References

[1] Lazar AJ,Bailey MH.Comprehensive and integrated genomic characterization of adult soft tissue sarcomas.Cell2017;171:950-65 PMCID:PMC5693358

[2] Chudasama P,Sanders MA.Integrative genomic and transcriptomic analysis of leiomyosarcoma.Nat Commun2018;9:144 PMCID:PMC5762758

[3] Wong J. 2018. Available from: https://www.mdpi.com/2077-0383/10/9/2028 [Last accessed on 2 August 2022].

[4] Ballinger ML,Ray-coquard I.Monogenic and polygenic determinants of sarcoma risk: an international genetic study.Lancet Oncol2016;17:1261-71

[5] Brohl AS,Turner CE.Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma.Genet Med2017;19:955-8 PMCID:PMC5529247

[6] Schultz KAP,Kamihara J.DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies.Clin Cancer Res2018;24:2251-61 PMCID:PMC6260592

[7] Hettmer S,Somers GR.Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers.Cancer2014;120:1068-75 PMCID:PMC4173134

[8] Evans DG,McGaughran J,Howard E.Malignant peripheral nerve sheath tumours in neurofibromatosis 1.J Med Genet2002;39:311-4 PMCID:PMC1735122

[9] Francom CR,Lovell MA.Head and neck pleomorphic myxoid liposarcoma in a child with Li-Fraumeni syndrome.Int J Pediatr Otorhinolaryngol2019;123:191-4

[10] Hensley ML,Solit DB.Genomic landscape of uterine sarcomas defined through prospective clinical sequencing.Clin Cancer Res2020;26:3881-8 PMCID:PMC7367750

[11] Network NCC. Genetic/familial high-risk assessment: colorectal (version 1.2021). 2021.

[12] Hampel H,Buchanan A.A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.Genet Med2015;17:70-87

[13] Gastrointestinal Stromal Tumor (GIST), NCCN, editor. 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf [Last accessed on 2 August 2022].

[14] Lupo PJ,Plon SE.Family history of cancer and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group and the Utah Population Database.Cancer Med2015;4:781-90 PMCID:PMC4430270

[15] Li H,Martin-Giacalone BA.Germline cancer predisposition variants in pediatric rhabdomyosarcoma: a report from the children’s oncology group.J Natl Cancer Inst2021;113:875-83 PMCID:PMC8246828

[16] Kim J,Subasri V.Pathogenic germline variants in cancer susceptibility genes in children and young adults with rhabdomyosarcoma.JCO Precis Oncol2021;5:75-87 PMCID:PMC8169077

[17] Diller L,Gottlieb A,Malkin D.Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.J Clin Invest1995;95:1606-11 PMCID:PMC295658

[18] Bougeard G,Flaman JM.Revisiting Li-fraumeni syndrome from TP53 mutation carriers.J Clin Oncol2015;33:2345-52

[19] Apellaniz-Ruiz M,Foulkes WD.DICER1-associated embryonal rhabdomyosarcoma and adenosarcoma of the gynecologic tract: Pathology, molecular genetics, and indications for molecular testing.Genes Chromosomes Cancer2021;60:217-33

[20] Warren M,Schmidt R.Expanding the spectrum of dicer1-associated sarcomas.Mod Pathol2020;33:164-74 PMCID:PMC7528621

[21] de Kock L,Apellaniz-Ruiz M.Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma.Moder Pathol2020;33:1207-19

[22] Miyama Y,Miyakawa J,Fukayama M.An autopsy case of prostatic rhabdomyosarcoma with DICER1 hotspot mutation.Pathol Int2021;71:102-8

[23] Doros L,Dehner L.DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome.Pediatric Blood Cancer2012;59:558-60 PMCID:PMC3708486

[24] Martin-Giacalone BA,Plon SE.Pediatric rhabdomyosarcoma: epidemiology and genetic susceptibility.J Clin Med2021;10:2028 PMCID:PMC8125975

[25] Miller RW.Tumors in rubinstein-taybi syndrome.Am J Med Genet1995;56:112-5

[26] Kratz CP,Etzler J.Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome.J Med Genet2009;46:418-20

[27] Mussa A,Baldassarre G.Cancer risk in beckwith-wiedemann syndrome: a systematic review and meta-analysis outlining a novel (Epi)genotype specific histotype targeted screening protocol.J Pediatr2016;176:142-149.e1

[28] Brioude F,Praz F.Mutations of the imprinted CDKN1C gene as a cause of the overgrowth Beckwith-Wiedemann syndrome: clinical spectrum and functional characterization.Human Mutat2015;36:894-902

[29] Valentin T,Ray-Coquard I.Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO).Eur J Cancer2016;56:77-84

[30] Stucky CC,Gray RJ.Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience.Ann Surg Oncol2012;19:878-85

[31] Ducatman BS,Piepgras DG,Ilstrup DM.Malignant peripheral nerve sheath tumors. a clinicopathologic study of 120 cases.Cancer1986;57:2006-21

[32] Wong WW,Scheithauer BW,Gunderson LL.Malignant peripheral nerve sheath tumor: analysis of treatment outcome.Int J Radia Oncol Biol Phys1998;42:351-60

[33] Anghileri M,Fiore M.Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution.Cancer2006;107:1065-74

[34] Evans DG,Birch JM.Malignant peripheral nerve sheath tumours in inherited disease.Clin Sarcoma Res2012;2:17 PMCID:PMC3499223

[35] Upadhyaya SA,Wilky BA.Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome.Pediatr Blood Cancer2018;65:e27030 PMCID:PMC5980703

[36] Eelloo JA,Bowers NL.Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.Fam Cancer2019;18:445-9

[37] King AT,Hammerbeck-Ward C.Malignant peripheral nerve sheath tumors are not a feature of neurofibromatosis type 2 in the unirradiated patient.Neurosurgery2018;83:38-42

[38] Agresta L,Hummel TR.Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2.Pediatr Blood Cancer2019;66:e27520

[39] Gargallo P,Juan A.Review: Ewing Sarcoma Predisposition.Pathol Oncol Res2020;26:2057-66

[40] Randall R,Jones K.Is there a predisposition gene for Ewing’s sarcoma?.J Oncol2010;2010:397632 PMCID:PMC2838402

[41] Hutter RV,Foote FW.Ewing’s sarcoma in siblings.Am J Surg1964;107:598-603

[42] Joyce MJ,Mankin HJ,Schiller AL.Ewing’s sarcoma in female siblings: a clinical report and review of the literature.Cancer1984;53:1959-62

[43] Abbott D,Schiffman J,Cannon-Albright LA.A population-based survey of excess cancers observed in Ewing’s sarcoma and in their first-, second-, and third-degree relatives. AACR, 2015. (ISBN No. 0008-5472).

[44] Venier RE,Kessler EM.A germline BARD1 mutation in a patient with Ewing Sarcoma: Implications for familial testing and counseling.Pediatr Blood Cancer2019;66:e27824

[45] Fernandez KS,Shah AT.Ewing sarcoma in a child with neurofibromatosis type 1.Cold Spring Harb Mol Case Stud2019;5:a004580 PMCID:PMC6824249

[46] Mehaffey C,Schaller T.Heterozygous PALB2 Mutation in a Boy with Acute Lymphoblastic Leukemia and Subsequent Metastatic Ewing Sarcoma.Klin Padiatr2021;233:141-4

[47] Kay RM,Mirra JM.Osteosarcoma and Ewing’s sarcoma in a retinoblastoma patient.Clin Orthop Relat Res1996;323:284-7

[48] Kleinerman RA,Abramson DH,Tarone RE.Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.J Natl Cancer Inst2007;99:24-31

[49] Sinclair TJ,Alvarez E,Spunt SL.Pleomorphic myxoid liposarcoma in an adolescent with Li-Fraumeni syndrome.Pediatr Surg Int2017;33:631-5

[50] Debelenko LV,Dubois SG.p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.Pediatr Dev Pathol2010;13:218-24

[51] Zare SY,Fadare O.Recurrent pleomorphic myxoid liposarcoma in a patient with li-fraumeni syndrome.Int J Surg Pathol2020;28:225-8

[52] Sui X,Zhao H.Giant liposarcoma of the esophagus with Li-Fraumeni-like syndrome.Eur J Cardiothorac Surg2011;40:1253-5

[53] Poli T,Caradonna L.Primary orbital liposarcoma in Li-Fraumeni cancer family syndrome: a case report.Tumori2005;91:96-100

[54] Sadri N,Fraker DL.Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation.Virchows Arch2014;464:505-9

[55] Yozu M,Dray M.Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field.Virchows Arch2013;462:355-60

[56] Kleinerman RA,Sigel BS.Bone and soft-tissue sarcoma risk in long-term survivors of hereditary retinoblastoma treated with radiation.J Clin Oncol2019;37:3436-45 PMCID:PMC7001778

[57] MacCarthy A,Brownbill P.Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004.British J Cancer2013;108:2455-63 PMCID:PMC3694232

[58] Schonfeld SJ,Abramson DH.Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors.British J Cancer2021;124:1312-9 PMCID:PMC8007574

[59] Ji J,Hemminki K.Familial risk for soft tissue tumors: a nation-wide epidemiological study from Sweden.J Cancer Res Clin Oncol2008;134:617-24

[60] Koczkowska M,Grzeszewska J,Biernat W.Primary leiomyosarcoma of the mesentery in two sisters: clinical and molecular characteristics.Pol J Pathol2013;64:59-63

[61] Kleinerman RA,Tarone RE.Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.J Clin Oncol2005;23:2272-9

[62] Wong FL,Abramson DH.Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.JAMA1997;278:1262-7

[63] Farid M.Sarcomas associated with genetic cancer predisposition syndromes: a review.Oncologist2016;21:1002-13 PMCID:PMC4978564

[64] Francis JH,Seddon JM.Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma.Gynecol Oncol2012;124:254-9 PMCID:PMC3264733

[65] Bright CJ,Winter DL.Risk of soft-tissue sarcoma among 69 460 five-year survivors of childhood cancer in Europe.J Natl Cancer Inst2018;110:649-60 PMCID:PMC6005019

[66] Jonsson P,Cheng ML.Tumour lineage shapes BRCA-mediated phenotypes.Nature2019;571:576-9 PMCID:PMC7048239

[67] Muller M,Guillaud-Bataille M.Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.Clin Genet2017;92:606-15

[68] Kraft S.Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma”.Am J Surg Pathol2011;35:599-607

[69] Villani A,Schiffman J.Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.Lancet Oncol2011;12:559-67

[70] de Andrade KC,Hatton JN.Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.Lancet Oncol2021;22:1787-98 PMCID:PMC8915249

[71] Robinson DR,Lonigro RJ.Integrative clinical genomics of metastatic cancer.Nature2017;548:297-303 PMCID:PMC5995337

[72] Le Guellec S,Rochaix P.CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics.Modern Pathol2012;25:1551-8

[73] Crago AM,Rosenberg M.Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis.Genes Chromosomes Cancer2015;54:606-15 PMCID:PMC4548882

[74] Fallen T,Morlan B.Desmoid tumors-a characterization of patients seen at Mayo Clinic 1976-1999.Fam Cancer2006;5:191-4

[75] Nieuwenhuis MH,Mathus-Vliegen LM,Hogendoorn PC.A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses.Int J Cancer2011;129:256-61

[76] Honeyman JN,Knowles MA.Desmoid fibromatosis in children and adolescents: a conservative approach to management.J Pediatr Surg2013;48:62-6

[77] Koskenvuo L,Lepistö A.Comparison of sporadic and FAP-associated desmoid-type fibromatoses.J Surg Oncol2017;116:716-21

[78] Koskenvuo L,Renkonen-Sinisalo L.Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis.J Surg Oncol2016;113:209-12

[79] Brennan B,Bourdeaut F.Extracranial rhabdoid tumours: what we have learned so far and future directions.Lancet Oncol2013;14:e329-e36

[80] Eaton KW,Wainwright LM,Biegel JA.Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.Pediatr Blood Cancer2011;56:7-15 PMCID:PMC3086793

[81] Bourdeaut F,Brugières L.Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor.Clin Cancer Res2011;17:31-8

[82] Foulkes WD,Evans DGR.Cancer surveillance in gorlin syndrome and rhabdoid tumor predisposition syndrome.Clin Cancer Res2017;23:e62-7 PMCID:PMC7309678

[83] Schneppenheim R,Gesk S.Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.Am J Hum Genet2010;86:279-84 PMCID:PMC2820190

[84] Nemes K,Bourdeaut F.Rhabdoid tumor predisposition syndrome. 2017.

[85] Hirota S,Moriyama Y.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.Science1998;279:577-80

[86] Ponti G,Martorana D.Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting.Oncol Rep2010;23:437-44

[87] Postow MA.Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications.Clin Sarcoma Res2012;2:16 PMCID:PMC3496697

[88] Nishida T,Taniguchi M.Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.Nat Genet1998;19:323-4

[89] Isozaki K,Belghiti J,Hirota S.Germline-Activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.Am J Pathol2000;157:1581-5 PMCID:PMC1885736

[90] Hirota S,Isozaki K.Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene.Gastroenterology2002;122:1493-9

[91] Chompret A,Barrois M.PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.Gastroenterology2004;126:318-21

[92] Janeway KA,Lodish M.Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.Proc Natl Acad Sci USA2011;108:314-8 PMCID:PMC3017134

[93] Miettinen M,Sarlomo-Rikala M.Succinate dehydrogenase deficient gists-a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric gists with predilection to young age.Am J Surg Pathol2011;35:1712

[94] Oudijk L,Korpershoek E.SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors.Mod Pathol2013;26:456-63

[95] Boikos SA,Killian JK.Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic.JAMA Oncol2016;2:922-8 PMCID:PMC5472100

[96] Zoller ME,Oden A,Angervall L.Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population.Cancer1997;79:2125-31